CoChat

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Background Ecnoglutide is a novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist currently in development for weight management. We aimed to assess the efficacy and safety of once weekly ecnoglutide versus placebo for the treatment of overweight or obesity in Chinese adults. Methods This randomised, double-blind, placebo-controlled, phase 3 trial was done at 36 medical centres across China. Eligible adults were aged 18-75 years with overweight or obesity (defined as BMI ≥28 kg/m 2 or ≥24 kg/m 2 with at least one weight-related comorbidity [prediabetes, hypertension, hyperlipidaemia, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnoea syndrome, or weight-bearing joint pain]), without diabetes (type 1 or 2). Participants were randomly assigned (3:3:3:1:1:1) via computer-generated random sequencing to receive subcutaneous ecnoglutide (1·2, 1·8, or 2·4 mg) or volume-matched placebo (1·2, 1·8, or 2·4 mg), once weekly, stratified by BMI at screening (≥28 kg/m 2 and 2 ). The coprimary endpoints were percentage change in bodyweight and proportion of participants with a reduction in bodyweight of 5% or more at week 40 (using the treatment policy estimand in the full analysis set). The full analysis set included all randomly assigned participants who were exposed to at least one dose of study drug or placebo according to their assigned treatment group. Safety was assessed in all participants who received at least one dose and had a sa…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(25)00141-x

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 3

  1. 2018, Expert consensus & standard on weight management for overweight or obese people, Zhonghua Jian Kang Guan Li Xue Za Xhi, 12, 200
  2. Guo, 2024, Biased GLP-1 analog ecnoglutide (XW003) has improved efficacy relative to unbiased peptides, Diabetes, 73, 793-P
  3. 2024, Guidelines for chronic weight management and clinical practice of anti-obesity medications (2024 version), Chin J Endocrino Metab, 40, 545

Cited by

See all 37

Metadata

Authors
Ji, L., Gao, L., Xue, H., Tian, J., Wang, K., Jiang, H., Huang, C., Lian, Q., Yuan, M., Gao, G., Lu, Y., Han, J., Fu, W., Wang, H., Zhang, Y., Shi, X., Wen, B., Shi, B., Hu, W., Guo, T., Xing, Y., Li, Y., Li, Q., Zheng, Q., Yang, M., Ning, J., Guo, M., Li, Y., & Pan, H.
Affiliations
  • Peking University People's Hospital (CN)
  • Binzhou Medical University (CN)
  • Nanjing Jiangning Hospital (CN)
  • First Affiliated Hospital of Henan University of Science and Technology (CN)
  • Yan'an University (CN)
  • Capital Medical University (CN)
  • Jinan Central Hospital (CN)
  • Second Affiliated Hospital of Nanjing Medical University (CN)
  • Jiangxi Pingxiang People's Hospital (CN)
  • China Medical University (CN)
  • Liaoning Provincial People's Hospital (CN)
  • First Affiliated Hospital of Soochow University (CN)
  • Second People’s Hospital of Huai’an (CN)
  • Xi'an Medical University (CN)
  • Second Affiliated Hospital of Zhengzhou University (CN)
Corresponding author
  • Ji, Linong
  • Zheng, Qing
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2025-09
Volume
13
Issue
9
Pages
777-789
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4411509867
Cited by
35
References
27
Citations by year
2026: 26 · 2025: 9
FWCI
19.94
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, obesity, overweight, weight loss, weight management, treatment policy estimand, Chinese adults, weight-related comorbidities, prediabetes, non-alcoholic fatty liver disease, obstructive sleep apnea
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Obesity, Treatment Outcome, Overweight, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(25)00141-x
The paper
Ji, L., Gao, L., Xue, H., Tian, J., Wang, K., Jiang, H., Huang, C., Lian, Q., Yuan, M., Gao, G., Lu, Y., Han, J., Fu, W., Wang, H., Zhang, Y., Shi, X., Wen, B., Shi, B., Hu, W., . . . Pan, H. (2025). Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(25)00141-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.